This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Karen Wagner
Managing Partner at Ysios Capital Partners


Dr. Karen Wagner is Managing Partner at Ysios Capital, a leading life sciences venture capital investor, where she focuses on therapeutic investments and coordinates the identification and evaluation of investment opportunities.

Prior to joining Ysios in 2008, Karen had over 10 years of experience in business development in various biotech and pharma companies. At GLYCART in Zurich, Switzerland, she worked together with Ysios colleague Joël Jean-Mairet. After the sale of GLYCART to F. Hoffmann-La Roche in 2005, she was responsible for business development and alliance management for Roche in the areas of drug discovery technologies, preclinical oncology and viral diseases. After leaving Roche, she managed a consultancy firm providing advice and hands-on support to various biotechnology companies in business development and strategy

Karen holds a Master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz.

Board positions

Karen serves on the Boards of Cytoki Pharma, Vivet Therapeutics, AELIX Therapeutics, Minoryx Therapeutics and SparingVision. Formerly, she was Board Member at Cardoz, Xeltis, Kala Pharmaceuticals (NASDAQ:KALA), and Galecto (NASDQ:GLTO).

Agenda Sessions

  • Fireside chat in collaboration with YVC Collective

  • Startup Spotlight Pitch Competition


Speakers at this event